The Supreme Court unanimously ruled that generic pharmaceutical manufacturers are not liable for patent infringement when doctors or pharmacists independently choose to use generic products for patented indications. This decision establishes a high legal threshold for active inducement, shielding companies that follow standard industry practices and legal requirements from liability for the conduct of third parties. It mirrors recent protections for internet service providers, signaling a judicial trend toward limiting secondary liability for organizations whose products are misused by their users.
Read the full article at SCOTUSblog
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
4
Ali NematiWritten by Ali
